Boehringer Ingelheim entered a potential $7.4 billion oncology-focused deal with China's SBP Group, as Fresenius formed a 37-asset biosimilar development collaboration with WuXi Biologics, and Evommune licensed an inflammatory disease molecular glue candidate from China's Hinova Pharma.
1. Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
Boehringer Ingelheim has penned a potential $7.4 billion biobuck pact with China’s SBP Group for a suite of preclinical T-cell engagers and antibody-drug conjugates. The deal follows a previous collaboration launched in late 2023. For SBP, the agreement underscores its discovery engine, which partly owes to the acquisition of LaNova Medicines last year.
2. Fresenius strikes WuXi Bio biosimilars deal for up to 37 assets, targeting €370B market
Fresenius has inked a sweeping partnership with WuXi Biologics to develop up to 37 biosimilar assets. The alliance expands Fresenius’ total biosimilar portfolio to 66 molecules, which together target an originator market estimated at roughly 370 billion euros. The fee-for-service agreement allows the German company to retain full commercialization economics of the resulting products.
3. Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as Novartis
Making a play in targeted protein degradation, Evommune signed a $1 billion licensing deal with China’s Hinova Pharmaceuticals for ex-China rights to a preclinical program targeting VAV1, which is implicated in several chronic inflammatory diseases. Novartis made a bet on the same target in a 2024 deal with Monte Rosa Therapeutics.
4. Pfizer looks to reroute supply after flooding sidelined India injectables plant
Pfizer is scrambling to reroute its sterile injectables supply chain after severe flooding sidelined a key manufacturing facility in India. The shutdown of the Zydus Hospira Oncology facility in Ahmedabad, Gujarat, is expected to last until mid-to-late 2028 as it threatens to compound existing shortages of chemotherapy drugs in the U.S.
5. AbbVie, Brise disclose $757M migraine deal signed in 2024 (release)
AbbVie and Brise Pharmaceuticals have just disclosed a deal they entered in 2024 around two of the Chinese biotech’s preclinical migraine programs. The potential value of the deal could reach $757 million, and Brise confirmed it has achieved several near-term milestones. For AbbVie, the deal strengthens its pipeline in migraine beyond established brands like Qulipta and Ubrelvy.
Other News of Note:
6. Hansoh hit with FDA write-up after inspection
7. Rhythm doubles down on LG obesity license, raising payout to as much as $855M
8. Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal
9. Cash-strapped Vivoryon regains China rights to kidney disease prospect from Simcere